Merck Serono and Ablynx sign third pact for nanomedicine R&D

11/9/2011 | Genetic Engineering & Biotechnology News

Ablynx will discover and develop osteoarthritis drugs with Merck Serono, marking the companies' third alliance that utilizes the former's nanobody platform. They previously agreed to work on therapeutic targets in oncology and immunology as well as inflammation. All three deals entitle Ablynx to upfront and milestone fees.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Briefs: